The recent biotechnology startup Neon Therapeutics has quickly put its $55m Series A venture capital to work with plans to begin a Phase Ib clinical trial in 2016 for the company's lead immunotherapeutic candidate in combination with the Bristol-Myers Squibb Co. immuno-oncology star Opdivo (nivolumab).
The recent biotechnology startup Neon Therapeutics has quickly put its $55m Series A venture capital to work with plans to begin a Phase Ib clinical trial in 2016 for the company's lead immunotherapeutic candidate in combination with the Bristol-Myers Squibb Co. immuno-oncology star Opdivo (nivolumab).
The Phase Ib trial will evaluate Cambridge, Massachusetts-based Neon's neoantigen-targeting therapeutic vaccine NEO-PV-01 plus the Bristol-Myers programmed cell death-1 (PD-1)...
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
